聚腺苷二磷酸核糖聚合酶的功能及其抑制剂潜在的临床应用

中国临床药理学与治疗学 ›› 2007, Vol. 12 ›› Issue (7): 743-747.

聚腺苷二磷酸核糖聚合酶的功能及其抑制剂潜在的临床应用

王慧源, 孙宏斌

中国药科大学新药研究中心, 南京 210009, 江苏

收稿日期:2007-02-01 修回日期:2007-04-11 出版日期:2007-07-26 发布日期:2020-10-27
通讯作者: 孙宏斌, 男, 研究员, 博士生导师, 研究方向:新药的分子设计与合成。Tel:025-85327950 E-mail:hbsun2000@yahoo.com
作者简介:王慧源,女,在读硕士,研究方向:抗肿瘤药物的设计合成。Tel:13813945825 E-mail:fruitjuicewang@126.com

Physiological functions of poly(ADP-ribose) polymerase and potential clinical applications of its inhibitors

WANG Hui-yuan, SUN Hong-bin

Center for Drug Discovery, China Pharmaceutical University, Nanjing 210009, Jiangsu, China

Received:2007-02-01 Revised:2007-04-11 Online:2007-07-26 Published:2020-10-27

摘要/Abstract

摘要： 聚腺苷二磷酸核糖聚合酶(PARP)是人体重要的酶之一, 参与染色质松弛、信号转录、DNA 修复和细胞凋亡等生理过程。PARP 过度激活则引起细胞坏死, 从而介导多种病理过程。因此, 抑制PARP可能会起到对某些疾病的治疗作用。本文综述了PARP 的功能及PARP 抑制剂的潜在临床应用。

关键词: 聚腺苷二磷酸核糖聚合酶, 抑制剂, DNA损伤修复, 细胞坏死

Abstract: Poly(ADP-ribose)polymerases(PARP)is one of the most important enzymes in human body.It plays an vital role in chromatin relaxation, signal transduction, DNA damage repair and apoptosis.Its over-activation induces necrosis and pathological processes.Therefore, inhibition of PARP may provide potential therapeutic approaches to treatment of a variety of diseases.This review presents an overview of PARP's functions and potential clinical applications of PARP inhibitors.

Key words: poly (ADP-ribose)polymerase, inhibitor, DNA damage repair, cell necrosis

中图分类号:

R969

王慧源, 孙宏斌. 聚腺苷二磷酸核糖聚合酶的功能及其抑制剂潜在的临床应用[J]. 中国临床药理学与治疗学, 2007, 12(7): 743-747.

WANG Hui-yuan, SUN Hong-bin. Physiological functions of poly(ADP-ribose) polymerase and potential clinical applications of its inhibitors[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(7): 743-747.

参考文献

1 Tentori L, Portarena I, Graziani G.Potential clinical applications of poly(ADP-ribose)polymerase inhibitors[J].Pharmacol Res, 2002;45:73-85.
2 Jagtap P, Szabo C.Poly(ADP-ribose)polymerase and the therapeutic effects of its inhibitors[J].Nat Rev Drug Discov, 2005; 4:421-440.
3 Hanai S, Uchida M, Kobayashi S, et al.Genomic organization of Drosophila poly(ADP-ribose)polymerase and distribution of its mRNA during development[J].J Boil Chem, 1998;273: 11881-11886.
4 Nguewa PA, Fuertes MA, Valladares B, et al.Poly(ADP-ribose) polymerases:homology, structural domains and functions.Novel therapeutical applications[J].Prog Biophys Mol Biol, 2005;88:143-172.
5 Davidovic L, Vodenicharov M, Affar EB, et al.Importance of poly(ADP-ribose)glycohydrolase in the control of poly(ADP-ribose) metabolism[J].Exp Cell Res, 2001;268:7-13.
6 Kun E, Bauer PI.Cell biological functions of PARP I:an overview[J].Ital J Biochem, 2001;50:15-18.
7 Yung TM, Sato S, Satoh MS.Poly(ADP-ribosyl)ation as a DNA damage-induced post-translational modification regulating poly(ADP-ribose)polymerase-1-topoisomerase I interaction[J]. J Biol Chem, 2004;279:39686-39696.
8 Flohr C, Burkle A, Radicella JP, et al.Poly(ADP-ribosyl) ation accelerates DNA repair in a pathway dependent on Cockayne syndrome B protein[J].Nucleic Acids Res, 2003;31:5332-5337.
9 von Kobbe C, Harrigan JA, Schreiber V, et al.Poly(ADP-ribose) polymerase 1 regulates both the exonuclease and helicase activities of the Werner syndrome protein[J].Nucleic Acids Res, 2004;32:4003-4014.
10 Virag L, Szabo C.The therapeutic potential of poly(ADP-ribose) polymerase inhibitors[J].Pharmacol Rev, 2002;54:375-429.
11 Ota K, Kameoka M, Tanaka Y, et al.Expression of histone acetyltransferases was downregulated in poly(ADP-ribose)polymerase-1-deficient murine cells[J].Biochem Biophys Res Commun, 2003;310:312-317.
12 Herceg Z, Wang ZQ.Failure of poly(ADP-ribose)polymerase cleavage by caspases leads to induction of necrosis and enhanced apoptosis[J].Mol Cell Biol, 1999;19:5124-5133.
13 Szabo G, Liaudet L, Hagl S, et al.Poly(ADP-ribose)polymerase activation in the reperfused myocardium[J].Cardiovas Res, 2004;61:471-480.
14 Casey PJ, Black JH, Szabo C, et al.Poly(adenosine diphosphate ribose)polymerase inhibition modulates spinal cord dysfunction after thoracoabdominal aortic ischemia-reperfusion[J]. J Vasc Surg, 2005;41:99-107.
15 Hua HT, Albadawi H, Entabi F, et al.Polyadenosine diphosphate-ribose polymerase inhibition modulates skeletal muscle injury following ischemia reperfusion[J].Arch Surg, 2005;140: 344-351.
16 Szabo G, Bahrle S, Sivanandam V, et al.Immunomodulatory effects of poly(ADP-ribose) polymerase inhibition contribute to improved cardiac function and survival during acute cardiac rejection[J].J Heart Lung Transplant, 2006;25:794-804.
17 Kiss L, ChenM, Gero D, et al.Effects of 7-ketocholesterol on the activity of endothelial poly(ADP-ribose)polymerase and on endothelium-dependent relaxant function[J].Int J Mol Med, 2006;18:1113-1117.
18 Rajesh M, Mukhopadhyay P, Godlewski G, et al.Poly(ADPribose) polymerase inhibition decreases angiogenesis[J].Biochem Biophys Res Commun, 2006;350:1056-1062.
19 Munoz-Gamez JA, Martin-Oliva D, Aguilar-Quesada R, et al. PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis[J].Biochem J, 2005;386:119-125.
20 Farmer H, McCabe N, Lord CJ, et al.Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy[J]. Nature, 2005;434:917-921.
21 Bryant HE, Schultz N, Thomas HD, et al.Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase[J].Nature, 2005;434:913-917.
22 Calabrese CR, Almassy R, Barton S, et al.Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361[J].J Natl Cancer Inst, 2004;96:56-67.
23 Stone DH, Al-Badawi H, Conrad MF, et al.PJ34, a poly-ADP-ribose polymerase inhibitor, modulates renal injury after thoracic aortic ischemia reperfusion[J].Surgery, 2005;138: 368-374.
24 Lobo SM, Orrico SR, QueirozMM, et al.Pneumonia-induced sepsis and gut injury:effects of a poly-(ADP-ribose) polymerase inhibitor[J].J Surg Res, 2005;129:292-297.
25 Gibson TM, Cotter MA, Cameron NE.Effects of poly(ADP-ribose) polymerase inhibition on dysfunction of non-adrenergic non-cholinergic neurotransmission in gastric fundus in diabetic rats[J].Nitric Oxide, 2006;15:344-350.
26 Nguewa PA, FuertesMA, Cepeda V, et al.Poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide enhances apoptosis induction by platinum complexes in cisplatin-resistant tumor cells[J].Med Chem, 2006;2:47-53.
27 Geraets L, Moonen HJ,Wouters EF, et al.Caffeine metabolites are inhibitors of the nuclear enzyme poly (ADP-ribose)polymerase-1 at physiological concentrations[J].Biochem Pharmacol, 2006;72:902-910.
28 Pacher P, Liaudet L, Mabley JG, et al.Beneficial effects of a novel ultrapotent poly(ADP-ribose)polymerase inhibitor in murine models of heart failure[J].Int J Mol Med, 2006;17:369-375.

[1]	郝潇, 赵美, 王文静, 张飞飞, 刘惠良, 党懿, 李树仁, 齐晓勇. 钠-葡萄糖共转运体2抑制剂在急性心肌梗死应用研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 824-831.
[2]	王娟, 刘维英, 叶育才, 付文丽, 张莎, 李乐萍. 去甲肾上腺素再摄取抑制剂联合抗毒蕈碱剂治疗阻塞性睡眠呼吸暂停的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 714-720.
[3]	沈嘉庆, 刘毅. 酪氨酸激酶2抑制剂治疗斑块型银屑病机制与临床研究进展[J]. 中国临床药理学与治疗学, 2023, 28(3): 323-330.
[4]	刘南玉, 岳红梅, 宋佩佩, 魏继芳, 魏雅倩, 谢莹莹, 王嘉琪. PDE4抑制剂作为肺纤维化的治疗靶点[J]. 中国临床药理学与治疗学, 2023, 28(3): 355-360.
[5]	黄小明, 杜野, 林少明, 沈观乐. 呼吸道微生态对晚期非小细胞肺癌患者接受PD-1抑制剂单药治疗疗效影响的探索性研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 66-74.
[6]	张可心, 贾文静, 崔佳文, 敖路遥, 周芳, 王广基, 刘嘉莉. 第三代EGFR酪氨酸激酶抑制剂在非小细胞肺癌临床治疗中的应用及研究进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1016-1030.
[7]	王金伙, 高新跃, 郭建荣. COX-2抑制剂对老年骨科手术患者术后谵妄的影响及其可能的作用机制[J]. 中国临床药理学与治疗学, 2022, 27(8): 863-869.
[8]	何雪茹, 付裕豪, 荀雪姣, 崔艳军, 董占军. 尿苷二磷酸葡醛酸转移酶介导的酪氨酸激酶抑制剂药物相互作用研究进展[J]. 中国临床药理学与治疗学, 2022, 27(8): 936-945.
[9]	刘南玉, 岳红梅, 宋佩佩, 魏继芳, 魏雅倩, 谢莹莹, 王嘉琪. 以αv为靶向的整合素作为肺纤维化的药物靶点[J]. 中国临床药理学与治疗学, 2022, 27(6): 709-714.
[10]	彭娟, 范琳琳, 李然宜, 李晓宇, 吕迁洲, 邹云增. 心力衰竭药物治疗的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 373-381.
[11]	王瑞杰, 王亮, 徐丹, 周淼淼, 李纪明. PCSK9抑制剂对冠心病患者血脂及炎症因子的影响[J]. 中国临床药理学与治疗学, 2022, 27(4): 409-417.
[12]	李远方, 崔兆强. 高血压合并高尿酸血症的应对之策[J]. 中国临床药理学与治疗学, 2022, 27(4): 428-432.
[13]	徐建飞, 林利. 高血压药物治疗与非药物治疗研究进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 433-441.
[14]	蒯铮, 张潇伊, 邹云增. 血管紧张素受体脑啡肽酶抑制剂在老年高血压中的应用[J]. 中国临床药理学与治疗学, 2022, 27(4): 442-445.
[15]	姚瑶, 夏敏, 侯聪, 何爱荣. ABT-737对TAMs与SKOV3细胞共培养中卵巢癌细胞生长与血管拟生作用的影响[J]. 中国临床药理学与治疗学, 2022, 27(2): 144-153.